Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Breast 2Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 361Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Lymphoma 297Leukemia 254Multiple Myeloma 246Leukemia, Myeloid, Acute 241Lymphoma, Non-Hodgkin 240Lymphoma, Large B-Cell, Diffuse 238Leukemia, Lymphocytic, Chronic, B-Cell 220Myelodysplastic Syndromes 184Lymphoma, Follicular 176Hodgkin Disease 165Lymphoma, Mantle-Cell 163Burkitt Lymphoma 160Lymphoma, B-Cell, Marginal Zone 117Recurrence 115Lymphoma, Large-Cell, Immunoblastic 95Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Myeloproliferative Disorders 81Melanoma 78Neoplasms, Plasma Cell 77Leukemia, Myeloid, Chronic-Phase 72Hematologic Neoplasms 72Leukemia, Myeloid, Accelerated Phase 71Leukemia, Myelomonocytic, Chronic 69Lymphoma, B-Cell 65Dendritic Cell Sarcoma, Interdigitating 64Triple Negative Breast Neoplasms 63Ovarian Neoplasms 61Congenital Abnormalities 59

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × Cyclophosphamide × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 6 charts
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡